Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237053 · ClinicalTrials.gov registry record · Phase 1
Effects of Glucagon Administration on Energy Expenditure
A Phase 1 study of Obesity and Hyperglucagonemia, sponsored by AdventHealth Translational Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02237053 is a Phase 1 study of Obesity and Hyperglucagonemia that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 6 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02237053, a Phase 1 study of Obesity and Hyperglucagonemia, has completed, sponsored by AdventHealth Translational Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
Conditions Studied
Interventions
- DRUG Insulin
- BEHAVIORAL Placebo
- DRUG Glucagon
- DRUG Octreotide
Study Locations (1)
Florida
- Florida Hospital Translational Research Institute for Metabolism and Diabetes - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237053
The ClinicalTrials.gov registry entry for NCT02237053 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Insulin is the first listed.
NCT02237053 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02237053 about?
NCT02237053 is a clinical study titled "Effects of Glucagon Administration on Energy Expenditure". The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
What is the current status of trial NCT02237053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-09. Estimated completion is 2016-06.
What conditions does trial NCT02237053 study?
This clinical trial studies the following conditions: Obesity, Hyperglucagonemia.
What interventions are being tested in trial NCT02237053?
The interventions under investigation include: Insulin (DRUG), Placebo (BEHAVIORAL), Glucagon (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT02237053?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02237053 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.